Research Dosing

CJC No DAC/Ipamorelin: 5/5mg

Growth hormone secretagogue and growth hormone releasing hormone (GHRH) analog blend. CJC-1295 No DAC is a synthetic GHRH analog that stimulates the anterior pituitary to release growth hormone (GH). Has a short half-life which leads to GH release in pulses, mimicking natural secretion patterns. Ipamorelin is a selective ghrelin receptor agonist (GHRP) that also stimulates GH release but without significant impact on cortisol or prolactin, and provides a synergistic boost when paired with CJC-1295 no DAC amplifying pulses.

Benefits

  • Promotes fat metabolism (lipolysis)
  • Supports lean muscle preservation and growth
  • Accelerates tissue healing (muscle, tendon, ligament)
  • Enhances exercise recovery and repair of microtrauma
  • Improved collagen synthesis for skin elasticity
  • Potential cosmetic/anti-aging applications studied in peptide medicine
  • GH release is linked to improved sleep quality
  • Possible improvements in energy, mood, and recovery from fatigue

What is the difference between CJC-1295 and CJC-1295 No DAC?

  • CJC-1295 with DAC (Drug Affinity Complex) includes an added component (DAC) that allows the peptide to bind to albumin in the blood, dramatically extending its half-life (to 6-8 days). This means that a single injection can elevate growth hormone (GH) and IGF-1 for up to a week, providing a sustained GH release over many days. The major disadvantage of this manner of dosing is the risk of desensitization due to the constant sustained GH elevation.
  • CJC-1295 No DAC is a shortened version of CJC-1295 DAC that has a much shorter half-life of only 30 minutes. However, its biological effects (GH pulse) last between 2 and 3 hours. Is typically administered 2-3 times per day to mimic natural pulsatile GH release (which more closely resembles the body’s natural secretion pattern). Less likely to lead to desensitization.

Possible Side Effects

  • Injection site reactions (redness, swelling, and/or itching)
  • Water retention (magnesium supplementation may reduce this)
  • Bloating
  • Mild fatigue or lethargy, usually immediately after dosing
  • Headaches
  • Flushing/Heat and/or a pins and needles sensation following dosing (can be mitigated by injecting as slowly as possible)
  • May stimulate hunger
  • Nausea
  • Hives
  • Dry mouth
  • Hyperactivity
  • Uncommon side effects: tingling or numbness in the extremities, joint pain or stiffness, lightheadedness or dizziness, nausea
  • Rare: Hypersensitivity/allergic reactions; rash; difficulty breathing; excess GH-like symptoms (acromegaly-like features): only with very high or prolonged misuse

Interactions

  • Insulin/Blood sugar regulation: may temporarily reduce insulin sensitivity
  • May interact with insulin therapy or oral hypoglycemics (metformin, sulfonulureas); monitor blood sugar carefully
  • Patients on thyroid medications may need dose adjustments
  • GH influences conversion of T4 ———> T3
  • High-dose or chronic corticosteroids (e.g. prednisone, dexamethasone) can blunt GH release, reducing efficacy
  • GH-induced fluid retention may reduce effectiveness of diuretics or worsen blood pressure control
  • Should be monitored in people on beta-blockers, ACE inhibitors, ARB’s or calcium channel blockers
  • Estrogen can reduce IGF-1 levels, potentially dampening benefits of GH secretagogues
  • Concurrent use with anabolic steroids, testosterone, SARMs, or other hormone therapies may cause synergistic effects on muscle growth, water retention, or joint stress
  • May contribute to dizziness or fatigue that could be compounded with sedatives, alcohol, or sleep medications
  • May synergize with GH-induced insulin resistance, causing unpredictable swings in blood sugar
  • May worsen insulin resistance

Contraindications

  • Do not use if pregnant or breastfeeding.
  • Do not use with active cancer (including pituitary adenomas).
  • Do not use with untreated hypothyroidism.
  • Use caution with blood-sugar regulation; monitor closely.
  • Risk of fluid overload, hypertension, or edema in those with severe cardiovascular disease
  • Do not use with uncontrolled diabetes mellitus
  • Do not use if you already have elevated GH/IGF-1 levels and/or acromegaly that make additional stimulation unsafe
  • Do not use if you have advanced stages of chronic kidney disease
  • Do not take if you have an unstable thyroid disorder
  • Not for use in critically ill patients
  • Do not use if you have an allergy to mannitol or other peptide components
  • If you determine that you are hypersensitive to this peptide, you should not continue use

Reconstitution and Dosing

12 week cycle, followed by 6-12 week washout period

Dose 5 consecutive days per week, followed by 2 rest (non-dosing) days

Dose at night, at least 2-3 hours after your last meal. Do not eat afterward.

Mix with 3mL (300 units) of BAC water

Standard Protocol

6-18 units, 1x/day, 5 days/week

Initial dose is 6 units, 1x/day. Gradually titrate up to as much as 15 unit, 1x/day throughout the duration of the cycle.

Maximum Protocol

12-30 units, 1x/day, 5 days/week

Initial dose is 12 units, 1x/day. Gradually titrate up to as much as 30 units, 1x/day throughout the duration of the cycle.

Synergistic Stacks

L-Carnitine — supports fatty-acid transport/oxidation during recomposition.

AOD-9604 — lipolysis support without glycemic impact.

BPC-157 and/or TB-500 — connective-tissue, tendon, and joint recovery alongside GH-mediated repair.